Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000809094 | SCV000949234 | likely benign | Ullrich congenital muscular dystrophy 2; Bethlem myopathy 2 | 2023-04-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001564747 | SCV001787956 | uncertain significance | not provided | 2019-04-26 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Centogene AG - |
RCV001809824 | SCV002059540 | uncertain significance | Ullrich congenital muscular dystrophy 2 | 2019-04-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003166281 | SCV003891046 | uncertain significance | Inborn genetic diseases | 2023-01-26 | criteria provided, single submitter | clinical testing | The c.5207A>G (p.D1736G) alteration is located in exon 29 (coding exon 28) of the COL12A1 gene. This alteration results from a A to G substitution at nucleotide position 5207, causing the aspartic acid (D) at amino acid position 1736 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |